Pulmonx Highlights $12 Billion Global Opportunity for Zephyr Valves in Investor Presentation
Bitget2026/10/27 20:31- Pulmonx reported third-quarter 2026 revenue of $22.8 million in an investor presentation, with US revenue of $14.9 million.
- Gross margin was 76%; cash, cash equivalents and marketable securities totaled $52.7 million as of September 30, 2026.
- The presentation estimated a $12 billion global opportunity for Zephyr valves across 1.2 million eligible patients.
- Investigational AeriSeal technology could expand the addressable market by at least 20% by making currently ineligible patients eligible for Zephyr treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
